Continuity of domestic formulations growth with increasing share of nonCovid portfolio is likely to drive Q2FY22 sales even as expected weakness in the US generics space could act as a spoiler for overall momentum. The Idirect healthcare universe (12 coverage companies) is expected to post YoY growth of ~5.5% to ~| 46123 crore. Domestic formulations (select pack) are expected to grow ~14% to | 11219 crore due to continuous traction from acute segment (momentum began from Q1) besides normalised trend in the chronic segment. We expect a significant shift in growth momentum from Covid to non-Covid portfolio on the back of receding active cases and growing vaccination drive across the country....